IP Library Granted Patent US 7,709,625
Granted Patent B2
US 7,709,625 · App. 11/199,465 · Granted May 4, 2010

Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy

Assignee: The Board of Regents of the University of Texas
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,709,625
App. No.
11/199,465
Granted
May 4, 2010
Kind
B2
Abstract

The present invention provides an isolated nucleic acid comprising a promoter operably linked to a nucleic acid encoding a peptide or protein and/or an RNA (e.g., antisense or ribozyme), wherein the promoter comprises elements that can include, but are not limited to, a) a myeloid specific promoter element comprising a core sequence GAGGAA; b) a myeloid specific promoter element comprising a core sequence AAGGAGAAG; c) a myeloid specific promoter element comprising a core sequence TTTCCAAA; d) a myeloid specific promoter element comprising a core sequence TGTGGTTGC; e) a myeloid specific promoter element comprising a core sequence TGAGTCA; f) a myeloid associated promoter element comprising a core sequence CCGCCC; and g) any combination of (a), (b), (c), (d), (e) and/or (f), any combination of multiples of (a), (b), (c), (d), (e) and/or (f), in any order and/or in any orientation (forward or reverse).

Claims (21)

1. An isolated nucleic acid comprising a promoter operably linked to a nucleic acid encoding a peptide or protein of interest, wherein the promoter comprises the following elements, in order: [C/EBPα forward]-[AM L-1 forward]-[PU.1A reverse]-[PU.1B reverse]-[PU.1A reverse]-[AM L-1 reverse]-[C/EBPα reverse]-[C/EBPα forward]-[AM L-1 forward] [PU.1B reverse] [PU.1A forward]-[Sp1 forward]-[Sp1 forward][C/EBPα forward]-[AM L-1 forward].

2. An isolated nucleic acid comprising a promoter operably linked to a nucleic acid encoding a peptide or protein of interest, wherein the promoter comprises the following elements, in order: [PU.1B reverse]-[C/EBPα forward]-[AM L-1 forward]-[C/EBPα forward]-[AM L-1 forward]-[PU.1B reverse]-[PU.1A forward]-[PU.1A forward]-[Sp1 reverse]-[AM L-1 reverse]-[C/EBPα reverse]-[PU.1A forward]-[PU.1B reverse]-[PU.1A forward].

3. The nucleic acid of claim 1 , wherein the peptide or protein of interest is a therapeutic peptide or protein.

4. The nucleic acid of claim 3 , wherein the peptide or protein is selected from the group consisting of: glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), neprilysin, lysosomal protective protein 1 cathepsin A (PPCA), insulin-like growth factor (IGF-1), glucocerebrosidase, liver X receptors, apoE, apoA1, ATP-binding cassette transporter A1 (ABCA1), gp91 phox , p47 phox , p67 phox and p22 phox .

5. A vector comprising the nucleic acid of claim 1 .

6. A cell comprising the vector of claim 5 .

7. An isolated nucleic acid comprising a promoter operably linked to a nucleic acid encoding a peptide or protein of interest, wherein the promoter comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:18 and the nucleotide sequence of SEQ ID NO:19.

8. A method of expressing a nucleic acid encoding a peptide or protein of interest in a myeloid cell, comprising introducing into the myeloid cell the nucleic acid of claim 1 .

9. The nucleic acid of claim 2 , wherein the peptide or protein of interest is a therapeutic peptide or protein.

10. The nucleic acid of claim 9 , wherein the peptide or protein is selected from the group consisting of: glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), neprilysin, lysosomal protective protein 1 cathepsin A (PPCA), insulin-like growth factor (IGF-1), glucocerebrosidase, liver X receptors, apoE, apoA1, ATP-binding cassette transporter A1 (ABCA 1), gp91 phox , p47 phox , p67 phox and p22 phox .

11. A vector comprising the nucleic acid of claim 2 .

12. A cell comprising the vector of claim 11 .

13. A method of expressing a nucleic acid encoding a peptide or protein of interest in a myeloid cell, comprising introducing into the myeloid cell the nucleic acid of claim 2 .

14. The nucleic acid of claim 7 , wherein the peptide or protein of interest is a therapeutic peptide or protein.

15. The nucleic acid of claim 14 , wherein the peptide or protein is selected from the group consisting of: glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), neprilysin, lysosomal protective protein 1 cathepsin A (PPCA), insulin-like growth factor (IGF-1), glucocerebrosidase, liver X receptors, apoE, apoA1, ATP-binding cassette transporter A1 (ABCA1), gp91 phox , p47 phox , p67 phox and p22 phox .

16. A vector comprising the nucleic acid of claim 7 .

17. A cell comprising the vector of claim 16 .

18. A method of expressing a nucleic acid encoding a peptide or protein of interest in a myeloid cell, comprising introducing into the myeloid cell the nucleic acid of claim 7 .

19. A hematopoietic stem cell comprising the vector of claim 5 .

20. A hematopoietic stem cell comprising the vector of claim 11 .

21. A hematopoietic stem cell comprising the vector of claim 16 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 21, 2017
From: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042068/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2005
From: LI, SENLIN; CLARK, ROBERT A.
To: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS, THE
Reel/Frame 016853/0272 →
Continuity (3)
Continuation In Part 1115066000 · Jun 10, 2005
Provisional Application 6057864600 · Jun 10, 2004
Related Publication 20060018889A1 · Jan 26, 2006